⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNKD News
Mannkind Corporation
MannKind Shares FUROSCIX® Business Updates
globenewswire.com
MNKD
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
globenewswire.com
MNKD
MannKind to Present at the Jefferies Global Healthcare Conference
globenewswire.com
MNKD
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
globenewswire.com
MNKD
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
globenewswire.com
MNKD
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
MNKD
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
globenewswire.com
MNKD
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
globenewswire.com
MNKD
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
MNKD
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
globenewswire.com
MNKD